Linden Thomas Advisory Services LLC Has $1.29 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Linden Thomas Advisory Services LLC increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,242 shares of the life sciences company’s stock after buying an additional 165 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Illumina were worth $1,287,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ILMN. Global Retirement Partners LLC grew its position in Illumina by 36.5% during the third quarter. Global Retirement Partners LLC now owns 714 shares of the life sciences company’s stock worth $99,000 after buying an additional 191 shares in the last quarter. Avior Wealth Management LLC boosted its holdings in Illumina by 9.9% during the third quarter. Avior Wealth Management LLC now owns 3,327 shares of the life sciences company’s stock valued at $457,000 after purchasing an additional 300 shares in the last quarter. Czech National Bank boosted its holdings in Illumina by 47.8% during the third quarter. Czech National Bank now owns 27,668 shares of the life sciences company’s stock valued at $3,798,000 after purchasing an additional 8,953 shares in the last quarter. Slow Capital Inc. boosted its holdings in Illumina by 6.6% during the third quarter. Slow Capital Inc. now owns 35,155 shares of the life sciences company’s stock valued at $4,826,000 after purchasing an additional 2,169 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC boosted its holdings in Illumina by 2.8% during the third quarter. Chevy Chase Trust Holdings LLC now owns 533,414 shares of the life sciences company’s stock valued at $73,227,000 after purchasing an additional 14,342 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ILMN. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Stephens reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Illumina in a report on Wednesday, April 10th. Barclays lifted their price objective on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Finally, StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $167.70.

Insider Buying and Selling at Illumina

In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.17% of the company’s stock.

Illumina Stock Performance

ILMN stock opened at $122.87 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The company has a 50 day moving average price of $132.44 and a 200 day moving average price of $127.54. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $228.13. The stock has a market capitalization of $19.57 billion, a PE ratio of -16.74 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the company posted $0.14 EPS. Illumina’s revenue was up 3.6% on a year-over-year basis. Analysts forecast that Illumina, Inc. will post 0.91 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.